Doripenem Intrapulmonary Pharmacokinetics in Healthy Adult Subjects

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2009-06-30

Study Completion Date

2010-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is being performed to measure the amount of the antibiotic doripenem (study drug) found in the fluid and cells of the lung and blood after receiving three doses of doripenem. The major objectives of this research are to see how much and for how long doripenem gets into the fluids and cells of the lungs of healthy adult subjects.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Phase 1 Randomized Double-blind Placebo Controlled Study to Evaluate Safety and PK of MEDI3902 in Healthy Adults

NCT02255760

MEDI3902 for Prevention of P. Aeruginosa Pneumonia

COMPLETED PHASE1

Doripenem in the Treatment of Hospital-Acquired Pneumonia

NCT00211003

Pneumonia

COMPLETED PHASE3

Doripenem in the Treatment of Complicated Lower Urinary Tract Infection or Pyelonephritis

NCT00210990

Urinary Tract Infections Pyelonephritis

COMPLETED PHASE3

An Open-label, Randomized, Single Period, Parallel-Cohort Study To Evaluate Serum and Pulmonary Pharmacokinetics Following Single and Multiple Dose Administration of Intravenous GSK2251052 in Healthy Adult Subjects

NCT01267968

Community-acquired Infection

COMPLETED PHASE1

Doripenem in the Treatment of Ventilator-Associated Pneumonia

NCT00211016

Pneumonia Ventilators, Mechanical

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The primary objective of this descriptive study is to determine and compare the plasma, epithelial lining fluid (ELF), and alveolar macrophages (AM) concentrations following multiple intravenous doses of doripenem in healthy, non-smoking adult subjects. In brief, each subject who qualifies for the study will be randomized to one of two dosing regimens: doripenem 500 mg or doripenem 1000 mg every 8 hours for a total of three intravenous doses. Each dose of doripenem will be administered as an intravenous infusion over 4 hours. Serial blood samples for determining plasma doripenem concentrations will be collected prior to and after the start of the intravenous infusion of the third doripenem dose. Each subject will undergo one standardized bronchoscopy with BAL in the outpatient bronchoscopy suite at one of four sampling times after the start of the intravenous infusion of the third doripenem dose. BAL collection will provide samples to determine drug concentration in ELF and AM. Safety will be assessed throughout the study by adverse event monitoring, clinical laboratory tests, and vital sign monitoring.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

HEALTH_SERVICES_RESEARCH

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Doripenem 500 mg

Group Type EXPERIMENTAL

Doripenem

Intervention Type DRUG

Intravenous 500 mg every (q) 8 hours for 3 doses

Doripenem 1000 mg

Group Type EXPERIMENTAL

Doripenem

Intervention Type DRUG

Intravenous 1000 mg q 8 hours for 3 doses

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Doripenem

Intravenous 500 mg every (q) 8 hours for 3 doses

Intervention Type DRUG

Doripenem

Intravenous 1000 mg q 8 hours for 3 doses

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Doribax Doribax

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy men and women at least 18 years of age who have no history of smoking within the last 1 year.
* Subjects must be healthy with no clinically important abnormalities in the medical history, physical examination, or laboratory values.